FIGURE 48. Cost-effectiveness of high-intensity statins (atorvastatin 20 mg/day) compared with no treatment, as a function of age and cardiovascular risk.

FIGURE 48

Cost-effectiveness of high-intensity statins (atorvastatin 20 mg/day) compared with no treatment, as a function of age and cardiovascular risk. (a) Unadjusted (as per CG181); and (b) adjusted for competing risk of non-cardiovascular death.

From: Appendix 8, Full results from cost–utility model assessing statins for the primary prevention of cardiovascular disease including adjustment for competing risk

Cover of The implications of competing risks and direct treatment disutility in cardiovascular disease and osteoporotic fracture: risk prediction and cost effectiveness analysis
The implications of competing risks and direct treatment disutility in cardiovascular disease and osteoporotic fracture: risk prediction and cost effectiveness analysis.
Health and Social Care Delivery Research, No. 12.04.
Guthrie B, Rogers G, Livingstone S, et al.
Copyright © 2024 Guthrie et al.

This work was produced by Guthrie et al. under the terms of a commissioning contract issued by the Secretary of State for Health and Social Care. This is an Open Access publication distributed under the terms of the Creative Commons Attribution CC BY 4.0 licence, which permits unrestricted use, distribution, reproduction and adaptation in any medium and for any purpose provided that it is properly attributed. See: https://creativecommons.org/licenses/by/4.0/. For attribution the title, original author(s), the publication source – NIHR Journals Library, and the DOI of the publication must be cited.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.